GSK plc Sponsored ADR (GSK)
India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs
India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.
GSK's speciality medicines arm gets the seal of approval from UK broker
Shore Capital has reiterated its ‘buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), highlighting the strength of its speciality medicines business as the driving force behind future growth. Despite challenges in the vaccines segment, the investment bank believes GSK remains well-positioned to meet its post-demerger growth targets.
Bear Of The Day: GSK PLC (GSK)
Healthcare stock investors have been feeling rather sick about the potential changes the Trump Administration may bring.
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks, GSK's focus on specialty medicines and stable margins make it a compelling blue-chip investment, currently undervalued.
GSK prelims get City thumbs up as investment banks upgrade
UBS has raised its target price for GSK PLC (LSE:GSK, NYSE:GSK) from £15.80 to £16, following a better-than-expected full-year earnings report and a focus on improving shareholder returns. The pharmaceutical company's 2025 guidance suggests 3-5% sales growth, despite anticipated weakness in vaccine sales and a £400-500 million impact from U.S.
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a stock buyback on the back of optimism about sales of its new drugs.
GSK plc (GSK) Q4 2024 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q4 2024 Earnings Conference Call February 5, 2025 5:45 AM ET Company Participants Dame Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Julie Brown - Chief Financial Officer David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants Emily Field - Barclays Bank Richard Parkes - BNPP Exane Peter Welford - Jefferies Steve Scala - TD Cowen Rajan Sharma - Goldman Sachs Justin Smith - Bernstein Graham Parry - Bank of America James Gordon - JPMorgan Chase Operator Hello, everyone. Welcome to today's call and webcast.
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales. The post GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion appeared first on Investor's Business Daily.
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago.
GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
Wednesday, GSK Plc GSK reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion.
GSK shares surge around 6% as drugmaker raises sales target and boosts dividends
Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and reported strong financial results for 2024. The stock climbed 5.9% in early trading, making it the top performer on the FTSE 100 and on track for its biggest one-day gain since 2022.
